UNSPSC 51191541: Clopamide

This classification denotes a diuretic with the molecular formula C14H20ClN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17S83WON0I, chemically known as 4-chloro-n-(2,6-dimethyl-piperidin-1-yl)-3-sulfamoyl-benzamide but generally known as clopamide, which bears US NIH Compound Identifier 2804. European Medicines Agency schedules Clopamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06735MIG.

UNSPSC 51191541 Clopamide is a Commodity code that state and local governments use to procure pharmaceutical products, though recent solicitations under this code span a broader range of chemical and pharmaceutical supplies than the code name alone suggests. The City of Meriden and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) demonstrate the actual scope of work: municipal water treatment chemical supplies (sodium bisulfite for water pollution control facilities) and generic multi-source pharmaceuticals and over-the-counter products distributed across state and local government healthcare facilities. State and local issuing bodies under this code include municipal water departments, state healthcare systems participating in cooperative purchasing vehicles, and multistate purchasing alliances. Insurance and bonding requirements vary by jurisdiction and commodity type—municipal chemical suppliers must carry General Liability coverage of $1,000,000 to $2,000,000 and performance bonds, while pharmaceutical vendors must maintain commercial general liability of $5,000,000 per occurrence and network security liability.

Recent solicitation activity appears concentrated in the Upper Midwest and Connecticut. The City of Meriden issued an IFB for sodium bisulfite with a due date of July 29, 2026. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement on behalf of participating state and local facilities including Oregon, issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with awards effective July 1, 2026 and contract terms through June 30, 2028. The MMCAP solicitation requires vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on all contract purchases. Pricing evaluation under MMCAP weighs price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative data format compliance, EDI capability, and administrative fee acceptance.